Abstract
Repeated TACEs did seem to have an impact on PVP. However, the increase in PVP had marginal effects with low portal hypertension-related complications.
Introduction
Transarterial chemoembolization (TACE) is a cornerstone of treatment for intermediate-stage hepatocellular carcinoma (HCC) and certain liver metastases. By delivering chemotherapy directly to the tumor and blocking its blood supply, TACE effectively targets cancer cells. However, the procedure inevitably affects healthy liver tissue, potentially causing cumulative damage that increases resistance to blood flow and raises portal venous pressure (PVP). This longitudinal study investigates whether repeated TACE procedures lead to a significant increase in PVP and associated clinical complications.
Methods
The researchers conducted a retrospective study of 99 patients (57 with HCC and 42 with liver metastases) who underwent a total of 279 TACE procedures. Because direct measurement of PVP is invasive, the study utilized non-invasive surrogate markers tracked via contrast-enhanced MRI and blood work:
- Spleen Volume: Measured using semi-automatic segmentation software on MRI.
- Platelet Count (PC): Monitored as a standard indicator of portal hypertension.
- Ascites and Portosystemic Collaterals: Graded based on longitudinal imaging.
The statistical analysis employed Generalized Estimating Equations (GEE) to account for the correlation between repeated measurements in the same patient over time.
Results
Spleen Volume as a Sensitive Marker
Spleen volume proved to be a more sensitive indicator of PVP changes than platelet counts. While platelet counts remained relatively stable over the long term (P > 0.05), spleen volume showed a clear upward trend. On average, spleen volume increased by 20 cm³ after the first TACE and continued to grow by approximately 16 cm³ per subsequent procedure.
Impact on Clinical Complications
The clinical impact of repeated TACE varied based on baseline liver health. Patients with "unstable" HCC (worsening Child-Pugh scores) were the most vulnerable, showing a 1.5x increase in the odds of developing moderate-to-severe ascites and a significant increase in portosystemic collaterals (P = 0.008). Conversely, metastatic patients saw a 0.5x decrease in the odds of developing severe ascites, likely due to reduced tumor burden.
Despite these measurable increases in surrogate markers, the actual rate of severe complications, such as variceal bleeding, was remarkably low (0.4%), suggesting that the liver's compensatory mechanisms are robust.
Discussion
This study demonstrates that while repeated TACE does lead to measurable changes in non-invasive markers of portal venous pressure, these increases are clinically marginal for most patients. The risk of serious portal hypertension-related complications remains low.
Limitations and Future Work
The study is limited by its retrospective design and reliance on surrogate markers rather than direct pressure measurements. Future prospective studies incorporating direct pressure measurements or newer non-invasive techniques like MR elastography could further refine the understanding of TACE-induced hemodynamic changes.
Summary updated